MyChesCo on MSN4mon
New Study Highlights XHANCE’s Efficacy in Treating Chronic Rhinosinusitis
YARDLEY, PA — Optinose (NASDAQ: OPTN) has announced the publication of a paper in the International Forum of Allergy & ...
Business Insider4d
Optinose Announces Preliminary Unaudited Fourth Quarter 2024 XHANCE Net Revenue of $22.4 Million
“Our preliminary unaudited fourth quarter net product revenue of $22.4 million is in line with our prior guidance and demonstrates a sustained growth in XHANCE prescriptions through the fourth ...